- Company
- Celltrion released the results of Regkirona's clinical trial
- by An, Kyung-Jin Jun 16, 2021 05:41am
- Celltrion is going to launch a global targeting of Regkirona (Regdanvimab), COVID-19 antibody treatment drug developed with its own technology. The government plans to eliminate controversy over efficacy and revitalize domestic and foreign markets through large-scale clinical trials. Celltrion held an online press conference on the morning
- Policy
- Ruling/opposition parties fight over supply & COVID vaccine
- by Lee, Jeong-Hwan Jun 15, 2021 05:53am
- Political circles of the ruling and opposition parties have launched a special committee on the COVID-19 vaccine and TF respectively, and are checking each other over the status of vaccine supply and vaccination performance. The ruling party has been announcing the results of COVID-19 vaccine since the Korea-U.S. summit, while the main opp
- Policy
- President Moon talks with AZ CEO at G7 Summit
- by Kim, Jung-Ju Jun 15, 2021 05:53am
- South Korean President Moon Jae-in met with Pascal Soriot, CEO of AstraZeneca, to ask for the company’s continuous support in supplying COVID-19 vaccines to Korea in the second half of this year. AstraZeneca responded positively to the request and replied that it hopes to continue a long-standing relationship with SK Bioscience as one of it
- Company
- The number of generics has been the lowest in 7 months
- by Chon, Seung-Hyun Jun 15, 2021 05:52am
- The number of Rx drugs' generic licences is the lowest in seven months since October last year. Recently, it was released in large numbers of generics for Atozet, but it fell back to its level shortly after the implementation of the drug price system. The proportion of consigned generics, which exceeded 80%, also fell to 50%. According to the
- Policy
- GC Pharma is working on developing DM combination drugs
- by Lee, Tak-Sun Jun 15, 2021 05:52am
- GC Pharma is busy building a lineup of ARB-based hypertension drugs called Candesartan. If Atacand, which is Candesartan's original product, has been sold for a long time, it can be seen as a measure to actively utilize its distribution network. It is currently pushing for development of other complexes in addition to single and two complexes
- Policy
- Hepatitis C Txs are rapidly being replaced with new drugs
- by Lee, Tak-Sun Jun 14, 2021 05:56am
- Chronic hepatitis C treatments are being withdrawn from the market as new drugs are released. Roche's Pegasys, a treatment for hepatitis B and C infection, eventually withdrew from the Korean market. Pegasys PFS products were revoked on the 8th. Pegasys, which was approved in Korea in 2004, was expected to be a hepatitis C treatment in
- Opinion
- [Reporter’s View] Fears cloud imminent RSA renewal
- by Eo, Yun-Ho Jun 14, 2021 05:56am
- With the Risk Sharing Agreement (RSA) contracts for major anticancer drugs soon to expire, stakeholders (government, pharmaceutical companies, patients) are faced with mixed concerns over the successful renewal of their RSA deals. In particular, the tension is tigher among pharmaceutical companies that have received or are planning to rec
- Product
- 5 mil Tylenols will be released to market…100 per pharmacy
- by Jun 14, 2021 05:56am
- ‘Public Tylenol will be supplied,’ ‘Why is the government unnecessarily supplying Tylenol to every pharmacy?’ On the 11th, the pharmacists’ community heat up over the Tylenol supply issue. The issue was sparked with some distributors spreading the news that ‘public rationed Tylenol will be released in the market from the 14th.'
- Company
- Second trial on patent dispute over Bonviva
- by Kim, Jin-Gu Jun 14, 2021 05:56am
- There will be a patent dispute over the osteoporosis drug Bonviva (Ibandronate) again. It is an analysis of damages worth &8361;tens of billions by domestic companies that are selling generics for Bonviva. According to the pharmaceutical industry on the 10th, British pharmaceutical company Atnahs Pharma, which owns patents of Bonviva,
- Company
- What's the future of vaccines after COVID-19 crisis?
- by Kim, Jin-Gu Jun 14, 2021 05:56am
- The rate of vaccinations against COVID-19 is increasing, especially in major developed countries. Experts say we need to brace ourselves for the 'Corona 21' and 'Corona 22' pandemic. As there is a high possibility that the pandemic will continue every year even if the current pandemic situation ends, the whole world should respond jointly. At
